Drug Approval | March 04, 2023
Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution
Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States
Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States
Rocuronium Bromide Injection is a neuromuscular blocking agent
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
he product will be launched shortly in the US market.
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
Jan Aushadhi Diwas celebrations to generate awareness about the usages of generic medicines and benefits of Jan Aushadhi Pariyojana
Sonowal exhorted young researchers and scientist to work on evidence based scientific research
Apixaban Tablets, 2.5 mg and 5 mg had annual sales of USD 18,876 mn in the United States (IQVIA MAT Dec. 2022).
Subscribe To Our Newsletter & Stay Updated
